Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment

被引:2
|
作者
Wan, Miaomiao [1 ]
Yang, Ke [1 ]
Zhang, Gonghao [2 ]
Yang, Chunxia [3 ]
Wei, Yuqing [3 ]
He, Yeqian [3 ]
Jiang, Xia [1 ,4 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Clin Pharm, Nanning, Peoples R China
[2] Guangxi Med Univ, Coll Clin Med 1, Nanning, Peoples R China
[3] Guangxi Med Univ, Coll Pharm, Nanning, Peoples R China
[4] Guangxi Med Univ, Affiliated Hosp 1, Dept Clin Pharm, Nanning 530021, Guangxi, Peoples R China
关键词
A Measure Tool to Assess Systematic Reviews 2; acute ischemic stroke; Cerebrolysin; Consolidated Health Economic Evaluation Reporting Standards 2022; rapid health technology assessment; METAANALYSIS; MANAGEMENT; RECOVERY;
D O I
10.1097/MD.0000000000037593
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study conducts a rapid health technology assessment to systematically evaluate the effectiveness, safety, and cost-effectiveness of Cerebrolysin as an adjunctive therapy for acute ischemic stroke to provide evidence-based medicine for clinical decisions of Cerebrolysin. All systematic reviews/meta-analyses, pharmacoeconomic studies, and health technology assessment reports of Cerebrolysin for the treatment of acute ischemic stroke before August 17, 2023, were retrieved from PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang, Weipu, Sinomed database and the official website of health technology assessment. According to the inclusion and exclusion criteria, 2 researchers independently carried out screening, data extraction, and quality evaluation and descriptively analyzed the results of the included studies. A total of 14 pieces of literature were incorporated, comprising 8 systematic reviews/meta-analyses and 6 pharmacoeconomic studies. In terms of effectiveness, compared to control groups, the use of Cerebrolysin as a treatment for acute ischemic stroke demonstrates certain advantages, including enhancement in total efficacy rate, neurological function, upper limb motor dysfunction, and facilitation of the recovery of activities of daily living. Especially in patients with moderate to severe acute ischemic stroke, Cerebrolysin has demonstrated the ability to enhance neurological function recovery and ameliorate disabilities. Regarding safety, adverse reactions were mild or comparable to those in the control group. The primary findings of economic studies reveal that advocating for the use of Cerebrolysin offers certain cost-effectiveness advantages. Cerebrolysin contributes to improved clinical efficacy and evaluation indexes while demonstrating favorable safety and economic benefits.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
    Ge, Pu
    Wan, Ning
    Han, Xiao
    Wang, Xinpei
    Zhang, Jinzi
    Long, Xiaoyi
    Wang, Xiaonan
    Bian, Ying
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study
    Strilciuc, Stefan
    Radu, Constantin
    Grad, Diana-Alecsandra
    Stan, Adina Dora
    Vladescu, Cristian
    Buzoianu, Anca Dana
    Muresanu, Dafin
    [J]. HEALTHCARE, 2023, 11 (10)
  • [3] COST-EFFECTIVENESS ANALYSIS OF CEREBROLYSIN IN THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE MODERATE AND SEVERE DEGREES OF SEVERITY IN THE RUSSIAN FEDERATION
    Kulikov, A.
    Abdrashitova, G.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A705 - A705
  • [4] TENECTEPLASE OR ALTEPLASE FOR ACUTE ISCHEMIC STROKE? A COST-EFFECTIVENESS ANALYSIS
    Nguyen, C.
    Lahr, M. M. H.
    Van der Zee, D. J.
    Van Voorst, H.
    Roos, Y. B. W. E. M.
    Uyttenboogaart, M.
    Buskens, E.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S167 - S167
  • [5] Systematic Review of the Cost and Cost-Effectiveness of Rapid Endovascular Therapy for Acute Ischemic Stroke
    Sevick, Laura K.
    Ghali, Sarah
    Hill, Michael D.
    Danthurebandara, Vishva
    Lorenzetti, Diane L.
    Noseworthy, Tom
    Spackman, Eldon
    Clement, Fiona
    [J]. STROKE, 2017, 48 (09) : 2519 - 2526
  • [6] COST-EFFECTIVENESS OF COMBINED TREATMENT WITH ALTEPLASE (RT-PA) AND CEREBROLYSIN IN ACUTE ISCHEMIC HEMISPHERIC STROKE IN AUSTRIA
    Walter, E.
    Bauer, M.
    Ressl, S.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A390 - A390
  • [7] Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials
    Zhang, Danfeng
    Dong, Yan
    Li, Ya
    Chen, Jigang
    Wang, Junyu
    Hou, Lijun
    [J]. BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [8] The Efficacy and Safety of Cerebrolysin in Acute Hemorrhagic Stroke: A Meta Analysis
    Shiong Shu, Leah L.
    San Jose, Christina Z.
    Pasco, Paul P.
    [J]. CEREBROVASCULAR DISEASES, 2012, 34 : 36 - 36
  • [9] Cost-effectiveness of endovascular therapy for acute ischemic stroke
    Chen, Michael
    [J]. NEUROLOGY, 2012, 79 (13) : S16 - S21
  • [10] The cost-effectiveness of telestroke in the treatment of acute ischemic stroke
    Nelson, R. E.
    Saltzman, G. M.
    Skalabrin, E. J.
    Demaerschalk, B. M.
    Majersik, J. J.
    [J]. NEUROLOGY, 2011, 77 (17) : 1590 - 1598